BRPI0922888A2 - administração combinada de fármaco - Google Patents

administração combinada de fármaco

Info

Publication number
BRPI0922888A2
BRPI0922888A2 BRPI0922888A BRPI0922888A BRPI0922888A2 BR PI0922888 A2 BRPI0922888 A2 BR PI0922888A2 BR PI0922888 A BRPI0922888 A BR PI0922888A BR PI0922888 A BRPI0922888 A BR PI0922888A BR PI0922888 A2 BRPI0922888 A2 BR PI0922888A2
Authority
BR
Brazil
Prior art keywords
drug administration
combined drug
combined
administration
drug
Prior art date
Application number
BRPI0922888A
Other languages
English (en)
Inventor
Gross Guenter
Tardio Joseph
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI0922888A2 publication Critical patent/BRPI0922888A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0922888A 2008-12-08 2009-11-27 administração combinada de fármaco BRPI0922888A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08170948 2008-12-08
PCT/EP2009/065943 WO2010066593A1 (en) 2008-12-08 2009-11-27 Combined drug administration

Publications (1)

Publication Number Publication Date
BRPI0922888A2 true BRPI0922888A2 (pt) 2019-09-24

Family

ID=41800658

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0922888A BRPI0922888A2 (pt) 2008-12-08 2009-11-27 administração combinada de fármaco

Country Status (12)

Country Link
US (2) US20100144853A1 (pt)
EP (1) EP2373344B1 (pt)
JP (1) JP5538423B2 (pt)
KR (1) KR101459181B1 (pt)
CN (1) CN102245211B (pt)
AU (1) AU2009326326B2 (pt)
BR (1) BRPI0922888A2 (pt)
CA (1) CA2744367A1 (pt)
IL (1) IL212603A (pt)
MX (1) MX2011005304A (pt)
SG (2) SG2013089776A (pt)
WO (1) WO2010066593A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164729A (en) * 2010-11-04 2018-01-30 Hoffmann La Roche A composition comprising s-[2- ( [ [1- (2-ethylbutyl) - cyclohexyl] - carbonyl]amino)phenyl] 2-methylpropanethioate and croscarmellose sodium
BR112013014291A2 (pt) * 2010-12-08 2016-09-20 Hoffmann La Roche formulação lipossômica de calcetrapib
BR112014027047A2 (pt) * 2012-04-30 2017-06-27 Hoffmann La Roche nova formulação
MX370538B (es) 2013-03-27 2019-12-17 Hoffmann La Roche Marcadores genéticos para la predicción de respuesta a la terápia.
WO2016016157A1 (en) 2014-07-30 2016-02-04 F. Hoffmann-La Roche Ag Genetic markers for predicting responsiveness to therapy with hdl-raising or hdl mimicking agent
CN110390494B (zh) * 2019-08-13 2022-04-26 成都理工大学 农业区生活垃圾填埋场地下水中“三氮”的溯源方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1401402B1 (en) * 2001-05-29 2016-09-07 Takeda Pharmaceuticals U.S.A., Inc. Enhancement of oral bioavailability of non-emulsified formulation of cefditoren pivoxil with lecithin
OA12619A (en) * 2001-06-21 2006-06-12 Pfizer Prod Inc Self-emulsifying formulations of cholesteryl estertransfer protein inhibitors.
EP1507813A4 (en) * 2002-05-20 2005-11-23 Ranbaxy Lab Ltd FAT BINDING USING AN INTERPOLYMER COMPLEX OF GLUCOSAMINE AND POLYACRYLIC ACID
US20040082675A1 (en) * 2002-10-28 2004-04-29 Schilling Steven L. Rigid foams and a process for the production of such foams
KR20080008440A (ko) * 2003-03-17 2008-01-23 니뽄 다바코 산교 가부시키가이샤 Ｃｅｔｐ 억제제의 약제학적 조성물
BRPI0408442A (pt) * 2003-03-17 2006-04-04 Japan Tobacco Inc método para aumento da biodisponibilidade oral de s-[2-([[1-(2-etilbutil)ciclohexil]carbonil]amino)fenil]2- metilpropanotioato
US6987118B2 (en) * 2003-05-21 2006-01-17 Pfizer Inc. Tetrahydroisoquinoline derivatives as PPAR-alpha activators
US7371759B2 (en) * 2003-09-25 2008-05-13 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
KR20070072888A (ko) * 2004-10-25 2007-07-06 니뽄 다바코 산교 가부시키가이샤 용해성 및 안정성이 개선된 고형 제제 및 그의 제조 방법
JP4482692B2 (ja) * 2005-04-26 2010-06-16 国立大学法人 熊本大学 Ｃａｃｏ−２細胞を用いたエステル含有化合物の消化管吸収性の予測方法
BRPI0618379A2 (pt) * 2005-11-08 2011-08-30 Ranbaxy Lab Ltd processo para preparação do hemi-sal de cálcio do ácido (3r,5r) -7-[2-(4-fluorofenil)-5-isopropil-3-fenil-4-[(4-hidroxime tilfenilamino) carbonil]-pirrol-1-il] -3, 5-diidroxi heptanóico

Also Published As

Publication number Publication date
WO2010066593A1 (en) 2010-06-17
IL212603A (en) 2015-09-24
EP2373344B1 (en) 2016-03-30
AU2009326326B2 (en) 2015-05-21
KR20110092297A (ko) 2011-08-17
SG172003A1 (en) 2011-07-28
SG2013089776A (en) 2015-07-30
MX2011005304A (es) 2011-06-01
CN102245211B (zh) 2013-05-22
AU2009326326A1 (en) 2010-06-17
JP2012511040A (ja) 2012-05-17
CA2744367A1 (en) 2010-06-17
EP2373344A1 (en) 2011-10-12
US20100144853A1 (en) 2010-06-10
CN102245211A (zh) 2011-11-16
JP5538423B2 (ja) 2014-07-02
US20160074360A1 (en) 2016-03-17
KR101459181B1 (ko) 2014-11-07
IL212603A0 (en) 2011-07-31

Similar Documents

Publication Publication Date Title
BRPI0920514A2 (pt) infusão de fármacos
DK2381988T3 (da) Medikamentadministrationsanordning
BRPI0920521A2 (pt) combinação farmacêutica
DK2296732T3 (da) Medikamentafgivelsesindretning
DK2073795T3 (da) Misbrugssikret lægemiddelformulation
DK2414011T3 (da) Medikamentafgivelsesindretning
DK2274032T3 (da) Anordning til medicinindgivelse
DK2274030T4 (da) Lægemiddelafgivelsesanordning
ATE531410T1 (de) Arzneimittelabgabevorrichtung
BRPI1010279A2 (pt) dispositivo de distribuição de fármaco
PL2136865T3 (pl) Podawanie donosowe
DK2632493T3 (da) Lægemiddelindgivelsessammensætninger
BRPI0820381A2 (pt) Formulações farmacêuticas
PL3005986T3 (pl) Infuzja leków
BRPI1012730A2 (pt) dispositivo de distribuição de fármaco
SMT201400069B (it) Formulazione farmaceutica
EP2419097A4 (en) PHARMACEUTICAL COMPOSITIONS
EP2451274A4 (en) Pharmaceutical compositions
BRPI1010237A2 (pt) dispositivo de distribuição de fármaco
BRPI0921654A2 (pt) formulação farmacêutica
PL2379086T3 (pl) Preparat farmeceutyczny
EP2236149A4 (en) MEDICAL COMPOSITION
DK2285413T3 (da) Farmaceutisk sammensætning
BR112012000799A2 (pt) dispositivo de distribuição de fármaco
DK2437736T3 (da) Lægemiddelindgivelsessystemer

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.